Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 31;95(8):679–684. doi: 10.1111/j.1349-7006.2004.tb03329.x

Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism

Shingo Maeda 1, Tsudoi Sugiura 1, Yoshiro Saikawa 1,✉, Tetsuro Kubota 1, Yoshihide Otani 1, Koichiro Kumai 1, Masaki Kitajima 1
PMCID: PMC11158986  PMID: 15298732

Abstract

We have examined the combined anticancer effects of docetaxel (DOC) and cisplatin (CDDP) in vitro using the gastric cancer cell lines MKN‐45, MKN‐74, and TMK‐1. Treatment of the cell lines with 30 μg/ml of DOC for 24 h followed by incubation with 3 or 10 μg/ml of CDDP for 24 h showed a clear synergistic effect. Sequence dependency of the agents was observed in these cell lines: DOC followed by CDDP (DC) showed a stronger antitumor effect than CDDP followed by DOC (CD) in all cell lines. To clarify the mechanism of action of the DC combination, total intracellular platinum (Pt) levels were evaluated after treatment with CDDP alone or combined with DC. For the MKN‐45 and ‐74 cell lines, cells treated with DOC (10 μg/ml for 12 h) and then CDDP showed significantly increased intracellular Pt accumulation compared to cells treated with CDDP alone. We also investigated alterations in intracellular glutathione (GSH) concentration in response to DOC and CDDP. MKN‐45 and ‐74 cells pretreated with DOC (10 μg/ml for 12 h) showed significantly increased intracellular GSH levels compared to cells administered CDDP only. To explain these findings, messenger RNA (mRNA) levels for multidrug resistance‐associated protein‐1 (MRP‐1), the ATP‐dependent pump for Pt‐GSH complexes, were quantified in CDDP‐treated MKN‐45 cells with and without DOC pretreatment. While CDDP administration increased MRP‐1 mRNA expression in MKN‐45 cells, MRP‐1 was not up‐regulated after CDDP administration in DOC pretreated MKN‐45 cells. Our results suggested that the enhanced CDDP toxicity due to DOC pretreatment may be related to the accumulation of intracellular Pt‐GSH complexes, because DOC appears to suppress the MRP‐1 up‐regulation induced by CDDP exposure in gastric cancer cells.

References

  • 1. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 70: 380–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Maeda S, Saikawa Y, Kubota T, Aoki M, Otani Y, Furukawa T, Watanabe M, Kumai K, Kitajima M. No cross‐resistance of taxotere and taxol to the conventional chemotherapeutic agents against gastric cancers as detected by MTT assay. Anticancer Res 2003; 23: 3147–50. [PubMed] [Google Scholar]
  • 3. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez‐Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK, Raber M. Phase II study of docetaxel for advanced or metastatic platinum‐refractory non‐small‐cell lung cancer. J Clin Oncol 1995; 13: 645–51. [DOI] [PubMed] [Google Scholar]
  • 4. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, Wimalasena J. Microtubule‐interfering agents activate c‐Jun N‐terminal kinase/stress‐activated protein kinase through both Ras and apoptosis signal‐regulating kinase pathway. J Cell Biol 1998; 273: 4928–36. [DOI] [PubMed] [Google Scholar]
  • 5. Kim R, Ohi Y, Inoue H, Toge T. Taxotere activates transcription factor AP‐1 in association with apoptotic cell death in gastric cancer cell lines. Anticancer Res 1999; 19: 5399–405. [PubMed] [Google Scholar]
  • 6. Perol M, Lena H, Thomas P, Robinet G, Fournel P, Coste E, Belleguic C, Le Caer H, Blanchon F, Vergnenegre A, Vernejoux JM, Schuller‐Lebeau MP, Pham E. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin‐vinorelbine with a cisplatin‐vinorel‐bine control group in patients with Stage IV non‐small‐cell lung cancer. Ann Oncol 2002; 13: 742–7. [DOI] [PubMed] [Google Scholar]
  • 7. Kim YH, Kim JS, Choi YH, In KH, Park HS, Hong DS, Jeong TJ, Lee YY, Nam E, Lee SN, Lee KS, Kim HK. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non‐small‐cell lung cancer. Int J Clin Oncol 2002; 7: 114–9. [DOI] [PubMed] [Google Scholar]
  • 8. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squa‐mous cell carcinoma of the head and neck. J Clin Oncol 2002; 15: 1593–9. [DOI] [PubMed] [Google Scholar]
  • 9. Pronk LC, Schellens JH, Planting AS, van den Bent MJ, Hilkens PH, van der Burg ME, de Boer‐Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G, Verweij J. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15: 1071–9. [DOI] [PubMed] [Google Scholar]
  • 10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63. [DOI] [PubMed] [Google Scholar]
  • 11. Suto A, Kubota T, Shimoyama Y, Ishibiki K, Abe O. MTT assay with reference to the clinical effect of chemotherapy. J Surg Oncol 1989; 42: 28–32. [DOI] [PubMed] [Google Scholar]
  • 12. Fukushima M, Okabe H, Takechi T, Ichikawa W, Hirayama R. Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity. Cancer Lett 2002; 187: 103–10. [DOI] [PubMed] [Google Scholar]
  • 13. Comis RI, Carter SK. Integration of chemotherapy into combined modality treatment of solid tumors. III. Gastric cancer. Cancer Treat Rev 1974; 1: 221–38. [DOI] [PubMed] [Google Scholar]
  • 14. Carter SK. Cancer treatment today and its impact on drug development with special emphasis on the phase II clinical trial. J Natl Cancer Inst 1976; 57: 253–344. [DOI] [PubMed] [Google Scholar]
  • 15. Schipper DL, Wagener DJT. Chemotherapy of gastric cancer. Anti-Cancer Drugs 1995; 7: 137–49. [DOI] [PubMed] [Google Scholar]
  • 16. Carter SK, Friedman M. Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1974; 1: 111–29. [DOI] [PubMed] [Google Scholar]
  • 17. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere R): a review of preclinical and clinical experience. Part 1: preclinical experience. Anti-Cancer Drugs 1995; 6: 339–68. [DOI] [PubMed] [Google Scholar]
  • 18. Bissery MC, Guenard D, Gueritte‐Voegelein F, Lavelle F. Experimental anti‐tumor activity of taxotere (RP 56976, NSC628503), a taxol analogue. Cancer Res 1991; 51: 4845–52. [PubMed] [Google Scholar]
  • 19. Chu G. Cellular responses to cisplatin. The roles of DNA‐binding proteins and DNA repair. J Biol Chem. 1994; 269: 787–90. [PubMed] [Google Scholar]
  • 20. Shen DW, Pastan I, Gottesman MM. Cross‐resistance to methotrexate and metals in human cisplatin‐resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998; 58: 268–75. [PubMed] [Google Scholar]
  • 21. Adachi S, Obaya AJ, Han Z, Ramos‐Desimone N, Wyche JH, Sedivy JM. c‐Myc is necessary for DNA damage‐induced apoptosis in the G(2) phase of the cell cycle. Mol Cell Biol 2001; 21: 4929–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Ishikawa T, Bao TT, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT. Coordinated induction of MRP/GS‐X pump and ‐glutamylcysteine syn‐thetase by heavy metals in human leukemia cells. J Biol Chem 1996; 271: 14981–8. [DOI] [PubMed] [Google Scholar]
  • 23. Rong R, He Q, Liu Y, Sheikh MS, Huang Y. TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3‐kinase/Akt and NF‐B signaling pathway. Oncogene 2002; 21: 1062–70. [DOI] [PubMed] [Google Scholar]
  • 24. Lai SL, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson BE, Mulshine JL, Ihde DC, Kayser K, Gazdar AF. MDR1 gene expression in lung cancer. J Natl Cancer Inst 1989; 81: 1144–50. [DOI] [PubMed] [Google Scholar]
  • 25. Hipfner DR, Gauldie SD, Deeley ROD, Cole SPC. Detection of the Mr 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 1994; 54: 5788–92. [PubMed] [Google Scholar]
  • 26. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999; 1461: 237–62. [DOI] [PubMed] [Google Scholar]
  • 27. Campling BG, Young LC, Baer K, Lam YM, Deeley RG, Cole SPC, Gerlach JH. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 1997; 3: 115–22. [PubMed] [Google Scholar]
  • 28. Young LC, Campling BG, Voskoglou‐Nomikos T, Cole SPC, Deeley RG, Gerlach JH. Expression of multidrug resistance protein‐related genes in lung cancer: correlation with drug response. Clin Cancer Res 1999; 5: 673–80. [PubMed] [Google Scholar]
  • 29. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001; 7: 1798–804. [PubMed] [Google Scholar]
  • 30. Endo K, Maehara Y, Kusumoto T, Ichiyoshi Y, Kuwano M, Sugimachi K. Expression of multidrug‐resistance‐associated protein (MRP) and chemosensitivity in human gastric cancer. Int J Cancer 1996; 68: 372–7. [DOI] [PubMed] [Google Scholar]
  • 31. Chan HLS, Lu Y, Grogan TM, Haddad G, Hipfner DR, Cole SPC, Deeley RG, Ling V, Gallic BL. Multidrug‐resistance protein (MRP) expression in re‐tinoblastoma correlates with the rare failure of chemotherapy despite cy‐closporine for reversal of P‐glycoprotein. Cancer Res 1997; 57: 2325–30. [PubMed] [Google Scholar]
  • 32. Filipits M, Stranzl T, Pohl G, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R. MRP expression in acute myeloid leukemia. In: Kaspers GJL, Pieters R, Veerman AJP, editors. Drug resistance in leukemia and lymphoma. vol. 3. New York : Kluwer Academic/Plenum Publishers; 1999. p. 141–50. [Google Scholar]
  • 33. Kamazawa S, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Takahashi M, Sato S, Akeshima R, Terakawa N. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. Oncology 2000; 59: 329–35. [DOI] [PubMed] [Google Scholar]
  • 34. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Cross‐resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 1993; 53: 5225–32. [PubMed] [Google Scholar]
  • 35. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T. Doxorubicin‐ and daunorubicin‐glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS‐X pump. Biochem Biophys Res Commun 1998; 247: 859–63. [DOI] [PubMed] [Google Scholar]
  • 36. Nishiyama M, Yamamoto W, Park JS, Okamoto R, Hanaoka H, Takano H, Saito N, Matsukawa M, Shirasaka T, Kurihara M. Low‐dose cisplatin and 5‐fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5: 2620–8. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES